Oli Pharma Launches Oligonucleotide CDMO Platform to Accelerate Nucleic Acid Drug Development

Mr. Zhao Hai, founder and general manager of Olipharma, stated in his speech: "As a technical service company dedicated to the nucleic acid drug field, we feel deeply honored to be able to contribute to this industry. With the official opening of Olipharma's oligonucleotide drug CDMO platform, we have reached an important milestone."

Subsequently, General Manager Zhao expressed heartfelt gratitude to the leaders at all levels, investors, teams, and partners for their care and support given to Olipharma.

In the future, Olipharma will steadfastly forge ahead to build a high-standard nucleic acid drug production platform and system in China, better serving nucleic acid innovative drug companies, accelerating the research and development and production of nucleic acid drugs, contributing Chinese strength to the industry's development, and shouldering the mission of "making nucleic acid drugs benefit the world!"

Subsequently, Mr. Gu Hongjian, member of the Party Working Committee and Deputy Director of the Management Committee of Wu Zhong Economic Development Zone in Suzhou, delivered a speech. Director Gu extended his warm congratulations on the opening of Olipharma's oligonucleotide drug CDMO platform.

He pointed out that Wuzhong Economic Development Zone, as the main battleground and primary engine for Wuzhong's economic development, has already attracted over 400 well-known enterprises, including Fortune 500 companies like Corning from the United States and GlaxoSmithKline, to establish operations. It is gradually becoming a highland for biopharmaceutical innovation in the Yangtze River Delta region with comprehensive R&D capabilities and a complete range of pharmaceutical categories.

Mr. Gu Hongjian mentioned that the technical team of Olipharma comes from one of the earliest groups in China to engage in the development of nucleic acid drug production processes and CMC research, with rich experience in project development and product registration. They have successively received honorary titles such as "Suzhou Innovative Small and Medium-sized Enterprise," "Top 100 Future Healthcare Enterprises by VCBeat," "2023 Dongwu Leading Talent in Innovation and Entrepreneurship," and "2023 Gusu Leading Talent in Innovation and Entrepreneurship." The successful establishment of Olipharma in Wuzhong Economic Development Zone will greatly promote the industrial clustering and industry development of the nucleic acid drug sector in Wuzhong District.

He emphasized that Wu Zhong Economic Development Zone's "industry-strong district, innovation-led" development strategy consistently supports the growth of enterprises within the zone, providing optimal services to businesses with dedication and effort, and jointly creating a bright future for Wu Zhong's biopharmaceuticals industry.

Mr. Li Jing, Vice President of Qingsong Capital, delivered a speech on behalf of the investors. He stated that nucleic acid drugs are currently a hot topic and frontier in the pharmaceutical field, possessing tremendous potential and broad application prospects. However, the development of the nucleic acid drug industry requires support from professional teams, capital, government departments, and individuals from all sectors of society. Olipharma, as a professional CDMO company for oligonucleotide drugs, will focus on helping customers address key challenges such as process scale-up and CMC control in small nucleic acid drug manufacturing. Qingsong Capital is an entrepreneurial private equity investment firm specializing in biotechnology and healthcare, with a management team that has deep industry backgrounds and extensive experience in private equity investment. On the occasion of this opening, let us wish Suzhou Olipharma Technology Co., Ltd. continued success and further important contributions to the development of nucleic acid drugs in China.

About Olipharma